10 February 2021
Eli Lilly announced that it has been granted emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) for combining investigational bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016). This combined antibody therapy is now authorised to treat mild to moderate Covid-19 symptoms among patients aged over 12 who are at high risk of severe Covid-19 and/or hospitalisation.
Go deeper with GlobalData
Bactiguard’s urinary catheter has been provided an Interim Order approval by Health Canada. The catheter has been approved with a temperature sensor to prevent infection. As many critically ill Covid-19 patients require a urinary catheter with temperature monitoring, the risk for additional bacterial infection arises. Bactiguard’s catheters reduce the risk of secondary infections for these critically ill hospitalised patients.
Moderna has signed two Covid-19 vaccine supply agreements: one with the Taiwan government to supply five million doses and another with the Colombia to supply ten million doses. The delivery of the vaccines will begin in mid-2021. The Covid-19 Vaccine Moderna is currently not approved for use in Taiwan or Colombia, but it is working with regulators to get the necessary approvals before distribution.
